Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acetyl-L-carnitine for dementia.

S Hudson1, N Tabet

  • 1Psychiatry, Maudsley Hospital, Maudsley Hospital, London, UK, SE5 8 AZ. s.hudson@iop.kcl.ac.uk

The Cochrane Database of Systematic Reviews
|June 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemic Cerebro-Spinal Meningitis: Extracts from an Essay Read before the Medical Association of Northeastern Ohio.

The Chicago medical journal·2023
Same author

Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.

Clinical toxicology (Philadelphia, Pa.)·2022
Same author

Isotonitazene, a novel psychoactive substance opioid, detected in two cases following a local surge in opioid overdoses.

QJM : monthly journal of the Association of Physicians·2022
Same author

Severe toxicity involving <i>N</i>-pyrrolidino etonitazene in the United Kingdom-a case report.

Clinical toxicology (Philadelphia, Pa.)·2021
Same author

Parenchymal pattern in women with dense breasts. Variation with age and impact on screening outcomes: observations from a UK screening programme.

European radiology·2018
Same author

Practical Efficiency Limit of Methylammonium Lead Iodide Perovskite (CH<sub>3</sub>NH<sub>3</sub>PbI<sub>3</sub>) Solar Cells.

The journal of physical chemistry letters·2018

Acetyl-l-carnitine (ALC) showed benefits in clinical global impression for dementia patients, but objective assessments found no cognitive improvements. Current evidence does not support routine ALC use in clinical practice.

Area of Science:

  • Neurology
  • Pharmacology
  • Geriatrics

Background:

  • Dementia affects 5% of individuals over 65, often linked to cholinergic system impairment.
  • Acetyl-l-carnitine (ALC) has properties potentially beneficial for dementia, including cholinergic activity and mitochondrial enhancement.
  • Despite research since the 1980s, ALC's efficacy in cognitive decline remains uncertain due to varied study methodologies.

Purpose of the Study:

  • To evaluate the clinical effectiveness of Acetyl-l-carnitine (ALC) in treating dementia patients.
  • To synthesize evidence from randomized controlled trials comparing ALC with placebo.

Main Methods:

  • Systematic review of double-blind, randomized trials of ALC versus placebo in people with dementia.
  • Searched the Cochrane Dementia and Cognitive Improvement Group's Specialized Register for relevant trials.

Related Experiment Videos

  • Extracted data, prioritizing intention-to-treat analyses, using Revman 4.1 software.

    • Main Results:

    • Eleven trials involving Alzheimer's disease patients were included; no trials included other dementia types.
    • ALC showed statistically significant benefits in Clinical Global Impression at 12 and 24 weeks, but not at 52 weeks.
    • No evidence of benefit was found for cognition, dementia severity, functional ability, or continuous Clinical Global Impression measures; adverse events did not differ significantly between groups.

    Conclusions:

    • Evidence suggests ALC may benefit the Clinical Global Impression in dementia, but objective measures show no other benefits.
    • The significant findings for Clinical Global Impression may be due to chance; routine clinical use is not currently recommended.
    • Further research is needed on ALC in diverse dementia types and for outcomes like mood and caregiver quality of life, alongside pharmacokinetic studies.